ADC Therapeutics price target raised to $10 from $7 on positive trial data

Guggenheim raised its price target on ADC Therapeutics (ADCT) to $10 from $7, maintaining a Buy rating, citing promising Phase 1b LOTIS-7 trial data for Zynlonta in relapsed/refractory DLBCL, which showed a 93.3% overall response rate. ADCT is undergoing restructuring, including a 30% workforce reduction and closure of UK operations, alongside a $100 million private placement to fund Zynlonta's clinical programs; however, InvestingPro data indicates the company is burning through cash with negative EBITDA of $124 million in the last twelve months.

Analysis

Guggenheim's recent upgrade of ADC Therapeutics' price target to $10.00 from $7.00, maintaining a Buy rating, is primarily attributed to positive interim data from the Phase 1b LOTIS-7 study of Zynlonta, which demonstrated a 93.3% overall response rate and an 86.7% complete response rate in relapsed/refractory diffuse large B-cell lymphoma patients. This clinical optimism, which has contributed to a 94% stock gain over the past six months, starkly contrasts with the company's financial metrics, including a negative EBITDA of $124 million in the last twelve months and significant cash consumption, as highlighted by InvestingPro. To address these financial pressures, ADC Therapeutics has secured a $100 million private placement and initiated a corporate restructuring, involving a 30% workforce reduction and closure of UK operations, aiming to extend its cash runway into 2028. Future prospects hinge on upcoming catalysts such as final LOTIS-7 data in H2 2025, LOTIS-5 Phase 3 results by year-end 2025, and potential regulatory discussions in 2026 for Zynlonta, which already has accelerated FDA and conditional European Commission approvals.

Key Decisions for Investors

• Investors should weigh the significant potential of Zynlonta, underscored by its 93.3% overall response rate in the LOTIS-7 trial and Guggenheim's increased $10 price target, against ADC Therapeutics' substantial cash burn ($124 million negative EBITDA) and reliance on recent financing.
• Closely monitor the company's execution on its restructuring plan and its progress in advancing Zynlonta through key clinical milestones, such as the LOTIS-7 final data in H2 2025 and Phase 3 LOTIS-5 results by end of 2025, as these are critical for sustaining operations and achieving regulatory success.
• Given the stock's 94% appreciation in the past six months, carefully evaluate the current valuation, considering the ongoing financial challenges, historical concerns regarding Zynlonta's sales performance, and the imperative for successful clinical data readouts and eventual commercial uptake.